FDA Opens First Line of Defense for Pet Prevention

The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Capstar (nitenpyram) tablets on September 3, 2026, and expanded the existing EUA for generic nitenpyram tablets from treatment to prevention and treatment. The authorization applies to dogs, puppies, cats, and kittens aged four weeks or older and weighing at least 2 pounds. This marks the first FDA-approved prevention indication for pets in response to New World screwworm (Cochliomyia hominivorax) in the U.S. While the current risk to U.S. pets remains low due to limited confirmed areas, the authorization provides a proactive option for pets living in or visiting infected regions to prevent tissue damage and death.

Repurposing an OTC Dewormer for Emergency Use

Capstar is an over-the-counter (OTC) medication already marketed for flea treatment, and nitenpyram is a neonicotinoid insecticide that disrupts nerve transmission by acting on nicotinic acetylcholine receptors (nAChR) in parasites. The regulatory status for the New World screwworm indication is EUA, not formal approval, and corresponds to an expanded indication for an already marketed product in an emergency setting. Two tablet strengths—11.4mg and 57mg—are available. For treatment, a second dose is administered six hours after the first, while for prevention, daily dosing is recommended to eliminate newly hatched larvae within 24 hours.

Linking Limited Clinical Evidence to Real-World Response

FDA data showed that in naturally infected beagles, 86% of larvae were expelled from wounds within six hours and 95.3% within 18 hours of the first dose, with the remaining larvae found dead. In a separate estimated Old World screwworm-infected dog study, all eight nitenpyram-treated dogs showed resolution within six hours. However, actual treatment requires physical removal of larvae, wound cleaning, debridement, and pain management. The preventive effect does not kill or prevent adult flies from laying eggs but prevents newly hatched larvae from establishing in wounds, so it does not replace wound care or exposure avoidance.

Competitive Landscape Shifts Toward Prevention Convenience

Competing products with the same indication include Boehringer Ingelheim’s NexGard (afoxolaner) and NexGard COMBO (eprinomectin, afoxolaner, praziquantel), Zoetis (ZTS)’s Simparica TRIO (sarolaner, moxidectin, pyrantel), and Elanco Animal Health (ELAN)’s Credelio CAT (lotilaner) and Credelio QUATRO-CA1. These products, either EUA or conditionally approved, have established the treatment market, but Capstar and its generic counterparts differentiate themselves through OTC accessibility and dual prevention-treatment coverage for both dogs and cats. The global companion animal deworming market was valued at USD 4.0793 billion in 2025, and this action is more appropriately viewed as a regulatory catalyst to expand nitenpyram’s usage frequency and distribution channels rather than a short-term revenue driver.

Regulatory History and Stakeholders Are Clear

HHS issued an emergency declaration for New World screwworm threats on August 18, 2025. The FDA first authorized generic nitenpyram from Felix Pharmaceuticals for treatment on June 11, 2026, and expanded it to prevention on September 3, 2026. On the same day, Capstar, sponsored by Sergeant’s Pet Care Products LLC dba PetIQ, received EUA for prevention and treatment. The authorization was issued under FD&C Act Section 564 without an advisory committee vote. EUA remains valid until the HHS declaration is lifted or the FDA revokes it, so the commercial value depends on the expansion of infected areas, repeat dosing demand, and the accumulation of efficacy and long-term safety data needed for formal approval.